Peter HodsonLuminex CorpLMNXBUYNov 07, 2008

Does pharmaceutical testing at a high throughput rate and saves pharmaceutical companies money. Just came out with great earnings. Good cost control.

Peter Hodson

Owned

Unlock Rating

$22.48

Stock price when the opinion was issued

$19.50

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Caller is asking about averaging down. You should never average down but you should average out with winners.

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Hightower

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Peter HodsonLuminex CorpLMNXBUYNov 07, 2008

You might be interested:

Luminex Corp(LMNX)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals